Ye X. and colleagues demonstrated that the overexpression of miR-375 restored the sensitivity of HER2-positive breast cancer cells to trastuzumab, most probably due to down-regulation of IGFR1 [103]. The gene discussed is ERBB2; the disease is breast cancer.